Avantor, Inc. (NYSE:AVTR) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue lessened its stake in shares of Avantor, Inc. (NYSE:AVTR) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 77,597 shares of the company’s stock after selling 1,375 shares during the period. State of Alaska Department of Revenue’s holdings in Avantor were worth $1,634,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Choreo LLC raised its position in shares of Avantor by 24.5% in the fourth quarter. Choreo LLC now owns 55,803 shares of the company’s stock valued at $1,176,000 after buying an additional 10,994 shares during the last quarter. DAVENPORT & Co LLC raised its holdings in Avantor by 21.2% in the 4th quarter. DAVENPORT & Co LLC now owns 2,844,362 shares of the company’s stock valued at $59,946,000 after acquiring an additional 496,990 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its stake in Avantor by 8.2% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 22,831 shares of the company’s stock worth $481,000 after purchasing an additional 1,727 shares in the last quarter. Norris Perne & French LLP MI boosted its holdings in shares of Avantor by 1.8% during the 4th quarter. Norris Perne & French LLP MI now owns 500,662 shares of the company’s stock worth $10,549,000 after purchasing an additional 8,966 shares during the last quarter. Finally, Forsta AP Fonden boosted its holdings in shares of Avantor by 3.3% during the 4th quarter. Forsta AP Fonden now owns 151,800 shares of the company’s stock worth $3,198,000 after purchasing an additional 4,900 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AVTR. Robert W. Baird reduced their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Wells Fargo & Company reduced their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday. UBS Group reissued a “neutral” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Royal Bank of Canada reduced their target price on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Raymond James reaffirmed an “outperform” rating and issued a $24.00 target price (down previously from $26.00) on shares of Avantor in a research report on Monday. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Price Performance

AVTR stock opened at $18.42 on Wednesday. Avantor, Inc. has a 1 year low of $18.19 and a 1 year high of $28.00. The firm has a market capitalization of $12.53 billion, a P/E ratio of 40.03, a P/E/G ratio of 3.87 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The business’s 50-day moving average is $21.68 and its two-hundred day moving average is $23.44.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the previous year, the firm posted $0.22 earnings per share. Analysts anticipate that Avantor, Inc. will post 0.98 earnings per share for the current fiscal year.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.